You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company plans to increase the capacity of its CLIA-certified laboratory to about 100,000 SARS-CoV-2 tests per day by the end of 2020.
Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.
The multiplexed paper-based assay could rapidly diagnose early-stage Lyme disease more accurately and at a lower cost than existing methods.
The partners will use a $5M NCI grant to add seven biomarkers to an EGFR electrochemical assay for non-small-cell lung-carcinoma.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
The technology uses a conducting polymer-based electrochemical chip with an array of electrodes and employs an electrical field to release and detect mutations.
Hong Kong-based Rainbow Genomics will provide exome sequencing while UCLA will interpret the data and deliver a clinical report.